Ascendant Diagnostics Receives ASTA Investment for Breast Cancer Detection

by Mark Carter  on Thursday, Jul. 25, 2013 12:11 pm   1 min read

Senior Scientist Anna Daily prepares a tear sample in Ascendant Diagnostics' Fayetteville lab.

Fayetteville biotech firm Ascendant Diagnostics has received a $300,000 investment from the Arkansas Science & Technology Authority for development of its MelodyDX product that uses tear samples to screen for breast cancer.

Want the Full Article?

Get Unlimited Archive Access for $19.95 per Year

Readers must pay to access articles older than 15 days.
Articles newer than 15 days are not included in this offer.

Purchase Now

Already have archive access? Login to view this article.